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Abstract
Ferrochelatase (FECH) is an enzyme necessary for heme synthesis, which is essential for
maintaining normal functions of endothelial nitric oxide synthase (eNOS) and soluble guany-
lyl cyclase (sGC). We tested the hypothesis that inhibition of vascular FECH to attenuate
heme synthesis downregulates eNOS and sGC expression, resulting in impaired NO/
cGMP-dependent relaxation. To this end, isolated bovine coronary arteries (BCAs) were in
vitro incubated without (as controls) or with N-methyl protoporphyrin (NMPP; 10−5–10-7M; a
selective FECH antagonist) for 24 and 72 hours respectively. Tissue FECH activity, heme,
nitrite/NO and superoxide levels were sequentially measured. Protein expression of FECH,
eNOS and sGC was detected by western blot analysis. Vascular responses to various vaso-
active agents were evaluated via isometric tension studies. Treatment of BCAs with NMPP
initiated a time- and dose-dependent attenuation of FECH activity without changes in its
protein expression, followed by significant reduction in the heme level. Moreover, ACh-
induced relaxation and ACh-stimulated release of NO were significant reduced, associated
with suppression of eNOS protein expression in NMPP-treated groups. Decreased relaxa-
tion to NO donor spermine-NONOate reached the statistical significance in BCAs incubated
with NMPP for 72 hours, concomitantly with downregulation of sGCβ1 expression that was
independent of heat shock protein 90 (HSP90), nor did it significantly affect BCA relaxation
caused by BAY 58–2667 that activates sGC in the heme-deficiency. Neither vascular
responses to non-NO/sGC-mediators nor production of superoxide was affected by NMPP-
treatment. In conclusion, deletion of vascular heme production via inhibiting FECH elicits
downregulation of eNOS and sGC expression, leading to an impaired NO-mediated relaxa-
tion in an oxidative stress-independent manner.
Introduction
Heme is an essential prosthetic group for hemoproteins that are involved in multiple physio-
logical processes, including oxygen transport and storage, oxidases and antioxidant defenses,
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mitochondrial respiration and electron transport, drug metabolism and protein biosynthesis,
etc. [1,2]. Ferrochelatase (FECH) is an important rate-limiting enzyme in heme biosynthesis,
during which, FECH operates the last enzymatic reaction by inserting ferrous iron (Fe2+) into
protophorphyrin IX (PpIX) [3–5]. It has been demonstrated that increases in oxidative stress,
as a general consequence of a variety of pathological procedures, impair FECH/heme regula-
tory processes via first, disrupting iron-sulfur clusters on FECH [6,7] to decrease its activity
[8], followed by reduction of heme synthesis. Second, the oxidation of heme present in some
heme-containing enzymes inactivates their enzymatic activity. In this context, oxidation of
soluble guanylyl cyclase (sGC) via converting heme from the ferrous (Fe2+) to ferric (Fe3+)
form has been documented as a key mechanism responsible for the peroxynitrite-dependent
attenuation of sGC activity [9–11]. Furthermore, oxidation of the sGC-heme causes a loss of
NO-stimulated cGMP production, associated with a proteolytic depletion of sGC in some vas-
cular diseases [12]. Heme-containing enzymes of endothelial nitric oxide synthase (eNOS) and
sGC are crucially implicated in the regulation of cGMP-controlled processes by NO, a pathway
that physiologically controls many cellular functions in the cardiovascular system [2,13]. Since
there are differences in sensitivities to the impact of heme deficiencies on the expression of
some hemoproteins [14,15], changes in heme biosyntheses are hypothesized to significantly
interrupt components of eNOS/sGC/cGMP signal transduction. Moreover, we have demon-
strated that in vivo treatment of mice with δ-aminolevulinic acid (ALA), a heme-synthesis
precursor that promotes PpIX-elicited activation of sGC, attenuated hypoxia-induced pulmo-
nary hypertension via preserving sGC/cGMP-dependent vasodilation [16,17]. Additionally,
impaired NO-mediated vasodilator responses of bovine coronary arteries (BCAs), as a func-
tion of angiotensin II (Ang II)-induced up regulation of mitochondrial superoxide elicited
disruption of FECH activity, a response that was normalized by treatment of BCAs with ALA
[18]. Moreover, miR-210 was reported to be able to compromise cardiac heme production by
targeting and inhibiting FECH [5], the study however, did not evaluate responsible functional
changes. Thus, while disrupting heme synthesis by oxidative stress to alter sGC/cGMP signal-
ing has been has been documented by our previous study [18], evidence is lacking indicating
the heme depletion-caused an interruption of eNOS synthesis/expression, as a function of
directly inhibiting FECH to deplete heme. While an in vivo inhibition of heme synthesis initi-
ated significant reductions in systemic nitrite/nitrate excretion and renal NOS activity of rats
[19], it is worth noting that the in vivo intervention of heme synthesis can initiate systemic
changes in multiple signal pathways and/or molecules involved, such as oxidations and anti-
oxidative defense or iron-sulfur cluster scaffold proteins and components of the electron trans-
port chain, etc., all of which may not necessarily be direct consequences of FECH inhibition or
heme loss, but rather a biological complexity that links multiple events operating in concert to
elicit responses observed. Additionally, most previous studies were focused on oxidative stress
that disrupts heme/NO/sGC/cGMP signaling involving both FECH/heme-dependent and
-independent mechanisms. To this end, the present study aimed to test the hypothesis that the
inhibition of FECH, followed by heme deficiency [14] directly downregulates eNOS and sGC
expression to alter NO/cGMP-mediated responses.
Materials and methods
Vessel culture
Freshly isolated bovine hearts were kept in ice-cold PBS and transported to the laboratory
within three hours from a local slaughterhouse (Cohen Max Insel Animal Organs & Tissues
for Research Inc, Livingston, NJ). BCAs were isolated from the branches of left anterior
descending arteries and cut into rings of 2 mm length under a dissecting microscope. BCAs
FECH and heme-containing enzymes
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were then placed in a 12-well dish filled with DMEM (Cellgro), supplemented with 10%
fetal bovine serum (v/v) and 1% antibiotics (Antimycin solution 100x), and incubated in the
absence (as controls) and presence of different concentrations of N-methyl protoporphyrin
(NMPP; 10−7–10-5M; a selective FECH antagonist) (Frontier Scientific, Logan, UT, USA)
under a 5% CO2 atmosphere at 37˚C for 24 and 72 hours respectively. DMEM containing
NMPP was prepared fresh and replaced every 12 hours.
Measurement of ferrochelatase (FECH) activity by HPLC-based assay
BCA rings were pulverized in liquid nitrogen. The crushed samples were mixed with a sam-
ple buffer (0.25 M TrisHCl buffer, pH 8.2, containing 1% Triton X-100 and 1.75 mM of pal-
mitic acid) in a concentration of 1 mg tissue per 100 μl buffer. Samples were incubated on
ice for 30 min and then centrifuged at 1000 g for 5 min. The supernatant was collected and
protein concentration was measured by Bio-Rad protein assay kit (Bio-Rad Laboratories,
Hercules, CA). 20 μl samples with protein concentration of 0.5 μg/μl were mixed with 5 μl of
protoporphyrin IX (PpIX; 250 μM). The reaction was initiated by adding 5 μl 200 μM zinc
acetate and incubated at 37˚C for 1 hour. After that, 170 μl dimethyl sulfoxide-methanol
(30:70) solution was added to stop the reaction. HPLC measurement of zinc protoporghyrin
(ZnPpIX) was used as an indicative of FECH activity with a Beckman ultrasphere C18 col-
umn (5 μm, 150 × 2 mm), a Jasco FP-1520 fluorescence detector, and 0.5 ml/min acetone-
methanol-water-formic acid (560:240:200:2) as the mobile phase. ZnPpIX was detected
based on the amount of fluorescence observed with excitation and emission wavelengths of
415 and 580 nm, respectively. Standard curves of ZnPpIX (0.1–5 picomole) were generated
using the sample buffer as a vehicle and used to calculate ZnPpIX formation, expressed as
picomoles per mg protein per minute.
Measurement of vascular heme
As described previously [20], BCA rings were washed several times with Krebs solution and
homogenized in 20 mM MOPS and 250mM sucrose buffer. Homogenates were centrifuged at
2,000 g for 5 min, and supernatant were assayed for protein content. 50 μl obtained from a 5
mg protein/ml supernatant were quantified for heme content using the QuantiChrom heme
assay kit (BioAssay Systems, Hayward, CA, USA). The absorbance at 400 nm was detected by
Synergy HT spectrophotometer (BIOTEK, Winooski, Vermont, USA). BCA heme levels were
reported as nanomoles per mg protein.
Western blot analysis
Frozen BCAs were pulverized in liquid N2. Equal amounts of total protein (25 μg) extracted
from samples were loaded on and separated by a 10% SDS-PAGE gel and transferred to a
PVDF membrane. The membrane was probed with specific primary antibodies for FECH
(Abcam, MA), eNOS (Santa Cruz Biotechnology, CA), sGCβ1 (Sigma, MO), vasodilator-
stimulated protein (VASP), phospho-VASP serine 239 (p-VASP) and heat shock protein 90
(HSP90) (Cell Signaling Technology, Danvers, MA), followed by appropriate secondary
antibodies conjugated with horseradish peroxidase. Specific bands were visualized with a
chemiluminescence kit and normalized to GAPDH. For mitochondrial FECH expression, the
mitochondrial protein of voltage-dependent anion channel (VDAC) was used as loading con-
trol. The X-ray film was scanned into a computer and band densitometry was digitalized with
UN-SCAN-IT software.
FECH and heme-containing enzymes
PLOS ONE | https://doi.org/10.1371/journal.pone.0200307 July 9, 2018 3 / 14
Isometric tension experiments
The method was described in detail previously [21]. Briefly, isolated BCA rings were mounted
on Danish myograph setups (DMT620M; Danish Myo Technology, Aarhus, Denmark) using
200 μm stainless steel pins and perfused with physiological salt solution (PSS) buffered with
95% air and 5% CO2 at 37˚C. The internal diameter and circumference of each ring was deter-
mined by the length of the ring and the known geometry of pins when the ring was stretched
to a level that generated the least stretching force. The average width (1.69 ± 0.07 mm and 1.61
± 0.06 mm for 24-h cultured groups, 1.55 ± 0.05 mm and 1.57± 0.06 mm for 72-h cultured
groups) and diameter (612.2 ± 46.2 μm and 654.5 ± 46.6 μm for 24-h cultured groups,
575.3 ± 38.9 μm and 583.6 ± 41.4 μm for 72-h cultured groups) of rings were comparable in
control and NMPP-treated rings. Based on the circumference, rings were further stretched in
a stepwise manner to establish a length-tension relationship. Using the length-tension curve, a
baseline force that was equivalent to a wall tension generated under 80 mmHg of intravascular
pressure was calculated and applied to the rings. The average baseline force (23.9 ± 2.9 mN
and 23.7 ± 2.8 mN for 24-h cultured rings, 20.6 ± 2.3 mN and 19.1 ± 2.7 mN for 72-h cultured
rings) and corresponding diameter of stretched rings (1429.4 ± 90.3 μm and 1406.0 ± 83.3 μm
for 24-h cultured vessels, 1248.2 ± 109.5 μm and 1178.1 ± 119.3 μm for 72-h cultured vessels)
were obtained from control and NMPP groups, respectively. All rings were equilibrated under
baseline force in PSS for one hour. In all studies, arterial rings were depolarized with 122 mM
KCl Krebs-bicarbonate buffer (high K+) to stabilize the reactivity of rings, followed by re-equil-
ibration with Krebs-bicarbonate buffer for additional 30 min. Then, the vessels were precon-
tracted with Krebs-bicarbonate containing 30 mM KCl (30K), and subsequently relaxed to
increasing cumulative concentrations of spermine-NONOate (10−8–10-5M), isoproterenol
(10−9–10-5M), acetylcholine (ACh, 10−8–10-5M) and Bay58-2627 (10−9–10-5M; Biovision Inc,
Atlanta, GA) respectively. Data were reported as percentage relaxation of the developed force
generated by 30K.
Basal and stimulated release of NO/nitrite in BCAs
The method was described in detail previously [22]. Briefly, the BCA rings were incubated in
96-well plates with 200 μl Krebs buffer (pH 7.4) with one segment of BCA rings in each well
for at 37˚C for 1 hour. The buffer was collected to assess the baseline level of nitrite. After that,
200 μl Krebs buffer containing 10-6M ACh were added into each well, followed by incubation
of the rings at 37˚C for 1 hour. After that, the buffer was once again collected to assess the
ACh-stimulated nitrite production. Nitrite formation was assessed using 2,3-diaminonaphtha-
lene (DAN) and a HPLC/fluorescence detector-based assay to determine 1-(H)-naphthotria-
zole, a fluorescent product upon the reaction of nitrite and DAN. 20 μl DAN dissolved in N,N-
dimethylformamide (5 mg/ml) and further diluted with 6 N HCl to 0.05 mg/mL, was added to
200 μl of the buffer and incubated for 10 min at room temperature. Then 20 μl of 10 N NaOH
was added. After a centrifugation, 20 μl of supernatant was separated by an HPLC system
(PU-2080 Plus; Jasco) with a C-18 reverse-phase column (Beckman Ultrasphere ODS, 5 μm,
4.6 × 250 mm). The mobile phase was composed of 35% acetonitrile and 50 mmol/L sodium
phosphate buffer (pH 8.5) and run at a flow rate of 0.5 ml/min. The fluorescent signal of 1-
(H)-naphthotriazole was detected at 375 nm (excitation) and 415 nm (emission) with a fluo-
rescence detector (FP2020 Plus; Jasco). The standard curve of sodium nitrite (0–640 μmol/L)
was generated and used to calculate nitrite formation in the sample, expressed as picomoles
per centimeter squared of the internal surface of vessels. The internal surface of BCA rings
were determined by mounting the rings on wire myograph apparatus and stretching rings to a
point that generates the least forces.
FECH and heme-containing enzymes
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Vascular superoxide production
As described previously [23], were incubated with dihydroethidium (DHE, 10−5 mol/l) for one
hour, during which the superoxide in the vessels reacted with DHE to form 2-hydroxyethi-
dium (EOH), which was detected by HPLC/fluorescence detector. After incubation with DHE,
the vessels were washed and homogenized in acetonitrile/water (1:1), and then centrifuged for
10 minutes. After centrifuging, the supernatant fraction was collected for HPLC analysis and
the precipitate was used for protein measurement using Bio-Rad Protein Assay (Bio-Rad, Her-
cules, CA). The final concentration of superoxide in each sample was normalized to the pro-
tein contents of their corresponding vessels, and expressed as picomoles of superoxide (EOH)
per microgram of protein.
Statistics
Data are represented as mean ± SEM, and n refers to the number of hearts. Statistical analyses
were performed using GraphPad Prism 6 software (Graph Pad Software Inc., San Diego, CA,
USA). Two-way ANOVA was used to compare dose-dependent vasodilator responses between
the control and NMPP-treated groups. Student’s t-test was used to compare the difference
between two groups. Statistical significance was accepted at a level of p< 0.05.
Results
Inhibition of FECH decreases heme content in BCAs
Fig 1a shows that the incubation of BCAs with NMPP for 24 hours (24-h) significantly reduced
their FECH activity in a dose-dependent manner, compared to control vessels. A time-depen-
dent inhibition of FECH activity by NMPP was also revealed, as indicated by the result that at
each concentration point, the reduced FECH activity was significantly greater in BACs treated
with NMPP for 72-hour (72-h) than those of 24-h. Additionally, 10-7M NMPP, did non-statis-
tically reduce FECH activity in the first 24 hours (P = 0.096), however, a statistically significant
inhibition was observed after extending incubation period to 72 hour (p = 0.031). Because our
preliminary results showed that the high dose of NMPP (10-5M) elicited an impaired vasocon-
strictor response after treating BCAs for 24-hour, whereas an effective inhibitory effect initi-
ated by the low dose of NMPP (10-7M) required a longer treating period. To this end, 10-6M
NMPP was selected as an optimal dose used in following experiments in order to ensure its
pharmacologically sufficient activity without interrupting with vascular contractility. As
shown in Fig 1b, in the presence of 10-6M NMPP, protein expression of FECH was not signifi-
cantly affected in the either group of vessels, suggesting a post-translational inhibition of
FECH. Fig 2 shows a time-dependent reduction in BCA heme levels in response to NMPP
treatment, suggesting the heme synthesis in a FECH-dependent manner.
NMPP reduces endothelium-dependent and –independent relaxation of
BCAs via impairing NO/sGC/VASP pathway
Next, functional evidence of the reduction in FECH activity is depicted in Fig 3. As indicated,
treatment of BCAs with NMPP for 72 hours (d-f) significantly attenuated ACh-induced relaxa-
tions (d), concomitantly associated with significant reductions in both basal and ACh-stimu-
lated release of nitrite/NO (e), verifying the failure of sufficient release of endothelial NO
leading to the impaired endothelium-dependent relaxation. Moreover, NMPP-treated BCAs
for 72-h displayed also, significant declines of spermine-NONOate (NO donor)-induced relax-
ations (f), suggesting impaired endothelium-independent responses attributed to reduction in
NO activating sGC. A similar responsive pattern was also presented in the group treated with
FECH and heme-containing enzymes
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Fig 1. (a) Changes in vascular ferrochelatase (FECH) activity in isolated bovine coronary arteries (BCAs) incubated
with difference doses of N-methyl protoporphyrin (NMPP;10−7, 10−6 and 10-5M) for 24 (24-h) and 72 hours (72-h),
respectively (n = 6–10). significant difference from their controls. #significant difference from 24-h group. (b)
Original and summarized data for FECH protein expression, normalized to voltage-dependent anion channel (VDAC)
in isolated BCAs incubated with 10-6M NMPP for 24 and 72 hours respectively (n = 3 blots).
https://doi.org/10.1371/journal.pone.0200307.g001
FECH and heme-containing enzymes
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Fig 2. Changes in vascular heme levels in BCAs cultured with NMPP (10-6M) for 24 and 72 hours respectively
(n = 12). significant difference from controls.
https://doi.org/10.1371/journal.pone.0200307.g002
Fig 3. Changes in vascular relaxations to Acetylcholine (ACh; a & d) and spermine-NONOate (c & f), as well as basal and stimulated release of
nitrite/NO (b & e) in BCA rings cultured with NMPP (10-6M) for 24 (a-c) and 72 (d-f) hours respectively. (n = 12–15). significant difference from
their controls. #significant difference from baseline controls. † significant difference between the two curves.
https://doi.org/10.1371/journal.pone.0200307.g003
FECH and heme-containing enzymes
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NMPP for 24 hours (a-c), which however, did not reach statistical significance (p = 0.15 and
p = 0.07 by two-way ANOVA for ACh and NONOare-induced dilations, respectively), imply-
ing that a time-dependent treatment was required to observe this action of NMPP. Thus, the
inhibition of vascular FECH (Fig 1) sequentially followed by the decrease in heme production
(Fig 2) appears to alter the heme-containing synthase enzymatic activities of eNOS and sGC,
leading to impaired NO-release and -mediated responses (Fig 3). This conclusion was verified
by data in Fig 4 showing that the inhibition of FECH with NMPP directly suppresses the pro-
tein expression of eNOS (a) and sGC (b). Using phosphor-VASP (at Ser239) as an index of
upstream-located sCG activation confirms a downregulation of p-VASP expression being as a
consequence of sCG inactivation (Fig 3c). Alternatively, NMPP that inhibited heme synthesis
to downregulate sGC did not significantly affect HSP90 expression (Fig 5a), neglecting the
possibility of suppression of sGC expression attributed to an altered expression of HSP90,
which in turn, leads to failure of inserting heme group into the enzyme [24,25]. Moreover, in
order to verify the impaired sGC-mediated relaxation (Fig 3) and sGC downregulation (Fig 4)
being heme-dependent in nature, separate experiments were performed aimed to assess vascu-
lar relaxation to Bay 58–2627, a vasoactive agent that specifically activates heme-depleted form
of sGC [26,27]. As shown in Fig 5b, Bay 58–2627 elicited a comparable dose-dependent relaxa-
tion in the control and NMPP-treated BCAs, revealing a normal vascular response to the heme
deficient component of sGC.
Effects of NMPP on BCA responses to non-NO responsive agents
To document the specificity originating from changes in eNOS/NO/sGC/cGMP signaling as a
function of inhibiting FECH/heme by NMPP, the mechanical properties of BCAs were deter-
mined by assessing their length-tension relationship and vascular responses to NO/sGC-inde-
pendent mediators. Fig 5 summarizes that the control and NMPP-treated BCAs exhibited an
identical response to the mechanical stretch, as indicated by their overlapped length-tension
curves (a & d). Additionally, vascular contractions manifested by the force development to 122
mM and 30 mM KCL respectively, (b & e) and relaxations to isoproterenol (c & f; β-adrenergic
receptor activator of cAMP) were comparable between NMPP-treated and –untreated groups
of BCAs. These results indicate that NMPP-induced changes (Figs 1–3) impact specifically on
vascular FECH/heme/eNOS/sGC signaling. Moreover, NMPP did not elicit changes in BCA
Fig 4. Changes in protein expressions of endothelial nitric oxide synthase (eNOS; a), soluble guanylyl cyclase-subunit 1 (sGCβ1; b) and
phosphorylation of vasodilator-stimulated phosphor-protein (p-VASP; c) in BCAs cultured with NMPP (10-6M) for 24 and 72 hours respectively.
(n = 5 blots for each group). significant difference from their controls.
https://doi.org/10.1371/journal.pone.0200307.g004
FECH and heme-containing enzymes
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superoxide production (Fig 6), suggesting that the observed changes in vascular function
caused by the NMPP-inhibition of FECH are independent of superoxide production.
Discussion
We provided direct evidence indicating that eNOS and sGC are two independent targets for
NMPP that inhibits FECH-dependent heme synthesis to downregulate eNOS and sGC expres-
sion, leading to impaired NO/sGC/cGMP-mediated vasodilator responses, which are indepen-
dent of vascular oxidative stress. Although accumulating evidence has indicated an oxidation-
dependent alteration of FECH/heme/sGC signaling in vasculatures, characterized as impaired
NO-mediated responses [12,16,18,24,28–30], two important points have not been unaddressed
yet, as what is direct effect of deleting FECH/heme on eNOS expression, and 2) whether an
alternative mechanism independent of oxidative stress is involved. Thus, the present study was
focused on direct correlation between the FECH/heme and two heme-dependent enzymes, via
assessing eNOS and sGC protein expression and activity, as a function of NMPP-inhibition of
FECH/heme without interruptions from oxidative stress.
Inhibition of vascular FECH/heme/eNOS/sGC/cGMP/relaxation by NMPP
We found that chronic incubation of BCAs with NMPP elicited a dose- and time-dependent
reduction in FECH activity, without significant changes in FECH protein expression (Fig 1),
suggesting a posttranslational-based event of NMPP, via most likely, instable of iron-sulfur
cluster assembly machinery of FECH [6]. As a result of inhibitory FECH activity, downstream
production of heme was concomitantly attenuated in a time-dependent manner (Fig 2),
revealing a FECH-specific suppression of heme biosynthesis. The dose of 10-6M NMPP was
selected because of its sufficiently inhibiting NMPP activity and heme production without
affecting normal vascular responsiveness. Functional changes in response to NMPP-induced
reductions in FECH activity and heme synthesis were evidenced by Fig 3 showing that after
Fig 5. Vascular protein expression of HSP90 (a; n = 8 for each group) and relaxation response to BAY58-2627 (b; n = 8 for each group) in BCAs in the
control condition and cultured with NMPP (10-6M) for 72 hours.
https://doi.org/10.1371/journal.pone.0200307.g005
FECH and heme-containing enzymes
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treatment of BCAs for 72 hours, endothelium-dependent ACh-induced vasodilation and
ACh-stimulated vascular release of NO were significantly attenuated. Moreover, endothelium-
independent relaxation by an exogenous NO donor that directly targets and activates sGC on
vascular smooth muscle to elicit cGMP-mediated relaxation, was also significantly reduced.
Thus, as downstream targets of FECH/heme, both eNOS and sGC are separately affected by
NMPP via inhibiting FECH to block heme synthesis. Noteworthy, functional alterations of
vessels (Fig 3) are correspondingly matched with changes in the heme level (Fig 2) and FECH
activity (Fig 1) as a function of NMPP, expressed as progressively declining relaxation during
24- to 72-hour incubation period, confirming the relationship among FECH, heme, eNOS,
sGC and cGMP in the signal transduction. In consistence with currently published findings
that FECH siRNA prevents ocular neovascularization via deleting FECH-induced angiogenesis
and also partially, suppressing eNOS expression [31], we indicated a direct downregulation of
eNOS expression (Fig 4a), accompanied with suppressing sGC protein expression (Fig 4b) by
NMPP, suggesting that while NMPP interferes with FECH activity at a post-translational level
(Fig 1), it initiates a post-transcritipnal downregulation of eNOS and sGC due perhaps, to
the result of deficient synthesis of heme (Fig 2). In this context, we provided explanations for
reductions in systemic nitrite/nitrate excretion and renal NOS and sGC activities, associated
with altered endothelium-dependent and –independent relaxations of aorta in response to in
vivo deleting heme synthesis of rats [19]. Of note, the significant downregulation of eNOS
in BCAs treated with NMPP for 24 hours (Fig 4a) elicited corresponding reductions in the
ACh-stimulated release of NO (Fig 4b), while vascular relaxation to ACh appeared to be pre-
served (Fig 3a). This phenomenon may attribute to the ACh compensatory release of non-NO
mediator(s), as a function of insufficient NO production, to maintain vascular relaxation [32].
Fig 6. Vascular wall tension in response to stretch-induced changes in radius (a & d), force development in response to stimulation with 122 mM
KCl (HK) and 30 mM KCl (30K) (b & e), and vascular relaxations to isoproterenol (c & f) in BCA rings cultured with NMPP (10-6M) for 24 (a-c)
and 72 (d-f) hours respectively. (n = 11–14).
https://doi.org/10.1371/journal.pone.0200307.g006
FECH and heme-containing enzymes
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Alternatively, the downregulation of sGC expression in response to NMPP treatment (Fig 4b)
did reflect corresponding impairment in its activity (Fig 3c). Consistently, a significant sup-
pression of vascular VASP phosphorylation by NMPP-treatement (Fig 4c) confirms the FECH
inhibition-dependent inactivation of sCG. Moreover, sufficient synthesis/level of heme is
essential for the maintenance of normal sGC function, which has been demonstrated in our
studies indicating a NMPP-induced reduction of heme synthesis, leading to the damage of
sCG function (Figs 1–4). Additionally, heme insertion also plays key roles during maturation
of sGC, a response that is driven by HSP90 [25,33], and inhibition of HSP90 is able to attenuate
sGC activity via increasing its degradation [34]. In our studies, the impaired sGC activity was
independent of HSP90-mediated pathway because NMPP did not change HSP90 expression
(Fig 5a) and activation of HSP90–associated heme-deficient (apo) sGC by BAY58-2627
remained normal in NMPP-treated BCAs (Fig 5b). This confirms our conclusions that the
impaired sGC is driven directly by NMPP inhibition of heme production.
NMPP-elicited changes in FECH/heme/eNOS/sGC/cGMP signaling
independent of oxidative stress, changes in vascular property and cAMP-
mediated pathway
As demonstrated (Fig 6), neither vessel responses to mechanical stretch (a & d) or smooth
muscle depolarization by high potassium (b & e), nor isoproterenol-induced cAMP-mediated
relaxation (c & f) was affected by NMPP treatment, verifying the specificity of NMPP-inhibi-
tion of vascular FECH/heme/eNOS/sGC/cGMP signaling. On the other hand, as a key player
in the mediation of cardiovascular dysfunction, oxidative stress potentially insults heme bio-
synthesis, via perhaps, disrupting FECH Fe-S cluster [7], a specific structure that is indispens-
able for maintaence of FECH stability and activity [6]. The consequences arising therefrom,
are characterized as the attenuation of heme-containing enzyme synthesis. Indeed, the one of
mechanisms responsible for oxidative stress-dependent deletion of sGC is considered to be
Fig 7. Vascular superoxide production, indicated by 2-hydroxyethidium levels in BCAs cultured with NMPP
(10-6M) for 24 and 72 hours respectively. n = 8.
https://doi.org/10.1371/journal.pone.0200307.g007
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due to an oxidation of sGC heme moiety-induced heme detachment from the enzyme, the
response that facilitates degradation of the enzyme by the ubiquitin-proteasome proteinlysis
pathway [35,36]. Moreover, the oxidant-dependent inactivate NO bioavailability has been well
documented [37]. Alternatively, aimed to identify a direct inhibition of FECH by NMPP in an
oxidative stress-independent manner, the present study was conducted on a physiologically-
based in vitro condition. The well preserved vascular responsiveness (Fig 6) and unchanged
vascular superoxide level (Fig 7) in BCAs treated with NMPP up to three days verify a specific
feature of the study, which differs from our, as well as others’ previous studies showing primar-
ily a superoxide-dependent deletion of sGC activity [9,10,16,18,29].
In conclusion, we provided direct evidence for the deletion of vascular heme production, as
a function of inhibiting EFCH without interference from oxidative stress, elicit deficiency of
downstream-located eNOS and sGC synthesis and activity, leading to impaired coronary vaso-
dilator responses specifically mediated by cGMP. Our findings shed light on the physiological
significance of FECH/heme involved in essentially operating vascular function. In addition,
during some pathological processes, FECH may serve as a therapeutic target with its activator
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